ROCKVILLE, Md., May 1, 2006 (PRIMEZONE) -- Cytomedix, Inc. (AMEX:GTF), a biotechnology company specializing in advanced treatments for chronic non-healing wounds, today announced that it has received commitments from existing warrant holders to exercise outstanding warrants totaling $2.2 million in proceeds to the Company. These proceeds will be used to further fund the Company's growth and development.
